Moderna Confirms Robust 93% Efficacy, Still Calls for Winter Boosters
In a surprising turn, Moderna Inc. has announced that its COVID‑19 vaccine retains a remarkable 93% effectiveness six months after the second dose. This figure is virtually identical to the 94% performance reported during its original clinical trial, giving a sigh of relief to anyone who thought the numbers might have dipped.
Why the Booster is Still on the Table
- Antibody Decline: Even though the long‑term data looks solid, antibody levels are expected to thin out as we head into the colder months.
- Third Shot Advocacy: Moderna, Pfizer, and BioNTech are all pushing for a third dose to keep protection at its peak.
- Seasonal Timing: Winter, with its shady re‑arrangements of social gatherings, could expose any gaps in immunity.
Q3 Earnings Call – Production Limits Aligned with Demand
During the second‑quarter earnings call, CEO Stephane Bancel revealed that the company will cap vaccine production at a range of 800 million to 1 billion doses this year. “We’re now capacity constrained for 2021, and we’re not taking any more orders for 2021 delivery,” Bancel said, indicating that rounds for the upcoming year remain full.
Stock Impact and Market Reaction
Following the announcement, Moderna shares dipped 3.6% to around $403.87 (S$545.36) in pre‑market trading after closing at $419.05 on Wednesday. While the drop is noticeable, the long‑term confidence in the vaccine’s performance seems intact.
Comparing the Numbers to Pfizer-BioNTech
Last week, Pfizer and BioNTech reported their own data, noting a steady 6% efficacy drop every two months. Their numbers softened to roughly 84% after six months, slightly lagging behind Moderna’s durable performance.
Shared Technology, Shared Promise
Both the Moderna and Pfizer-BioNTech vaccines harness messenger RNA (mRNA) technology, a ground‑breaking scientific approach that’s become the new benchmark for vaccine evolution.
“Our COVID‑19 vaccine shows durable efficacy of 93% through six months, but the Delta variant remains a significant new threat, so we must remain vigilant,” Bancel stated, underscoring the need for continued vigilance.
World Health Officials Debate Hazard vs. Benefit
- Safety: Are additional doses safe enough for broad roll‑outs?
- Effectiveness: Can we truly expect higher protection from a third shot?
- Necessity: Is a booster mandatory in the face of the Delta spike?
While some nations, such as Israel, have already begun or are planning to administer boosters for older or more vulnerable people, Pfizer aims to secure third‑shot approval later this month—in parallel to ongoing global discussions.
BOOSTER CANDIDATES
Moderna’s Booming Boosters and Business Pulse
Boosters that Pack a Punch – Moderna’s latest work on three different booster shots has shown impressive antibody surges against the Gamma, Beta and Delta variants. The neutralising titers after the third jab are eyeballing the levels hit with the initial two‑dose course.
Sales Power‑Play
Moderna’s vaccine contracts for 2024 are already tracking at a hefty $20 billion in projected sales. The company closed $12 billion in deals this year, with options that could add roughly another $8 billion. Production plans aim for 2 billion to 3 billion doses next year, keeping the supply line steady.
Pfizer, the industry giant, is racing ahead with a forecast of 3 billion doses for the same period and a 2023 sales climax of $33.5 billion. Still, Moderna’s vaccine passed US emergency‑use approval in December and now enjoys emergency or conditional clearance in over 50 countries.
Regulatory Milestone
This month, Moderna plans to submit its full‑approval dossier to the U.S. Food and Drug Administration—a big step toward permanent market status.
Quarterly Highlights
- Q2 Sales – $4.4 billion, nudging ahead of the $4.2 billion forecast from 10 Refinitiv analysts.
- Revenue – $2.78 billion, translating to $6.46 per share, comfortably outpacing the expected $5.96 a share.
- Historical Comparison – The COVID‑19 shot’s first‑year sales were a modest $67 million.
As Moderna’s vaccine continues to roll out worldwide, the company’s financial runway looks strong, and the booster data sets a promising tone for future growth.
